Neoleukin Therapeutics (NLTX) Competitors

$27.71 +0.10 (+0.36%)

As of 05/22/2026

NLTX vs. ALVO, AKTS, EVO, CRON, and SVRA

Should you buy Neoleukin Therapeutics stock or one of its competitors? MarketBeat compares Neoleukin Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Neoleukin Therapeutics include Alvotech (ALVO), Aktis Oncology (AKTS), Evotec (EVO), Cronos Group (CRON), and Savara (SVRA). These companies are all part of the "pharmaceutical products" industry.

How does Neoleukin Therapeutics compare to Alvotech?

Neoleukin Therapeutics (NASDAQ:NLTX) and Alvotech (NASDAQ:ALVO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

Alvotech has a consensus target price of $7.60, indicating a potential upside of 127.54%. Given Alvotech's stronger consensus rating and higher probable upside, analysts clearly believe Alvotech is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Neoleukin Therapeutics has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market. Comparatively, Alvotech has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market.

Neoleukin Therapeutics has a net margin of 0.00% compared to Alvotech's net margin of -14.36%. Alvotech's return on equity of -11.92% beat Neoleukin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
Alvotech	-14.36%	-11.92%	-7.58%

Alvotech has higher revenue and earnings than Neoleukin Therapeutics. Alvotech is trading at a lower price-to-earnings ratio than Neoleukin Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
Alvotech	$588.90M	1.71	$27.92M	-$0.25	N/A

In the previous week, Alvotech had 3 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 3 mentions for Alvotech and 0 mentions for Neoleukin Therapeutics. Neoleukin Therapeutics' average media sentiment score of 0.00 beat Alvotech's score of -0.21 indicating that Neoleukin Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
Alvotech	Neutral

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by insiders. Comparatively, 0.5% of Alvotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Alvotech beats Neoleukin Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to Aktis Oncology?

Aktis Oncology (NASDAQ:AKTS) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Aktis Oncology's return on equity of 0.00% beat Neoleukin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Neoleukin Therapeutics	N/A	-37.22%	-30.91%

28.8% of Aktis Oncology shares are held by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are held by institutional investors. 3.3% of Aktis Oncology shares are held by insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Aktis Oncology presently has a consensus price target of $32.00, suggesting a potential upside of 57.33%. Given Aktis Oncology's stronger consensus rating and higher possible upside, research analysts clearly believe Aktis Oncology is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Aktis Oncology had 6 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 6 mentions for Aktis Oncology and 0 mentions for Neoleukin Therapeutics. Neoleukin Therapeutics' average media sentiment score of 0.00 beat Aktis Oncology's score of -0.62 indicating that Neoleukin Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aktis Oncology	Negative
Neoleukin Therapeutics	Neutral

Aktis Oncology has higher revenue and earnings than Neoleukin Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	167.10	N/A	N/A	N/A
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A

Summary

Aktis Oncology beats Neoleukin Therapeutics on 8 of the 10 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to Evotec?

Evotec (NASDAQ:EVO) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

Evotec presently has a consensus price target of $7.00, indicating a potential upside of 131.02%. Given Evotec's stronger consensus rating and higher possible upside, analysts clearly believe Evotec is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Evotec had 3 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 3 mentions for Evotec and 0 mentions for Neoleukin Therapeutics. Evotec's average media sentiment score of 0.02 beat Neoleukin Therapeutics' score of 0.00 indicating that Evotec is being referred to more favorably in the media.

Company	Overall Sentiment
Evotec	Neutral
Neoleukin Therapeutics	Neutral

Neoleukin Therapeutics has lower revenue, but higher earnings than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$891.97M	1.21	-$117.12M	N/A	N/A
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A

Evotec has a beta of 1.96, meaning that its share price is 96% more volatile than the broader market. Comparatively, Neoleukin Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

Neoleukin Therapeutics has a net margin of 0.00% compared to Evotec's net margin of -26.20%. Evotec's return on equity of -24.93% beat Neoleukin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
Neoleukin Therapeutics	N/A	-37.22%	-30.91%

5.8% of Evotec shares are held by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are held by institutional investors. 1.0% of Evotec shares are held by insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Evotec beats Neoleukin Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to Cronos Group?

Cronos Group (NASDAQ:CRON) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

Cronos Group has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, Neoleukin Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market.

Cronos Group has higher revenue and earnings than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	$146.59M	7.03	-$9.45M	$0.01	274.00
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A

8.7% of Cronos Group shares are owned by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 7.8% of Cronos Group shares are owned by company insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Neoleukin Therapeutics has a net margin of 0.00% compared to Cronos Group's net margin of -1.14%. Cronos Group's return on equity of -1.26% beat Neoleukin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cronos Group	-1.14%	-1.26%	-1.20%
Neoleukin Therapeutics	N/A	-37.22%	-30.91%

Cronos Group presently has a consensus target price of $2.30, suggesting a potential downside of 16.06%. Given Cronos Group's stronger consensus rating and higher possible upside, analysts plainly believe Cronos Group is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Cronos Group's average media sentiment score of 0.33 beat Neoleukin Therapeutics' score of 0.00 indicating that Cronos Group is being referred to more favorably in the media.

Company	Overall Sentiment
Cronos Group	Neutral
Neoleukin Therapeutics	Neutral

Summary

Cronos Group beats Neoleukin Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to Savara?

Neoleukin Therapeutics (NASDAQ:NLTX) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

In the previous week, Savara had 14 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 14 mentions for Savara and 0 mentions for Neoleukin Therapeutics. Neoleukin Therapeutics' average media sentiment score of 0.00 beat Savara's score of -0.19 indicating that Neoleukin Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
Savara	Neutral

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Savara shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Neoleukin Therapeutics has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market. Comparatively, Savara has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market.

Savara has a consensus price target of $9.13, suggesting a potential upside of 81.77%. Given Savara's stronger consensus rating and higher probable upside, analysts plainly believe Savara is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Savara	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Savara is trading at a lower price-to-earnings ratio than Neoleukin Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
Savara	N/A	N/A	-$118.84M	-$0.56	N/A

Neoleukin Therapeutics' return on equity of -37.22% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
Savara	N/A	-87.19%	-66.42%

Summary

Savara beats Neoleukin Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Neoleukin Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NLTX vs. The Competition

Export

Metric	Neoleukin Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$260.42M	$927.43M	$6.46B	$12.34B
Dividend Yield	N/A	4.84%	2.76%	5.28%
P/E Ratio	-8.91	1.46	21.22	25.66
Price / Sales	N/A	119.63	562.28	86.31
Price / Cash	N/A	20.07	43.49	56.67
Price / Book	2.50	7.59	10.31	7.14
Net Income	-$57.56M	-$3.64M	$3.57B	$335.98M
7 Day Performance	-0.96%	3.01%	6.43%	4.15%
1 Month Performance	2.52%	76.62%	3.57%	2.54%
1 Year Performance	60.36%	126.61%	34.07%	35.06%

Neoleukin Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NLTX Neoleukin Therapeutics	N/A	$27.71 +0.4%	N/A	+60.4%	$260.42M	N/A	N/A	90	High Trading Volume
ALVO Alvotech	3.3154 of 5 stars	$3.30 +0.6%	$7.60 +130.3%	-67.5%	$989.92M	$588.90M	N/A	1,460	Analyst Downgrade
AKTS Aktis Oncology	1.7925 of 5 stars	$19.03 +2.9%	$32.00 +68.2%	N/A	$987.99M	$8.28M	N/A	76
EVO Evotec	2.8195 of 5 stars	$2.84 +2.2%	$7.00 +146.5%	-35.9%	$987.80M	$891.97M	N/A	4,553
CRON Cronos Group	1.4039 of 5 stars	$2.67 +2.3%	$2.30 -13.9%	+35.0%	$982.07M	$146.59M	267.27	450

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NLTX) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neoleukin Therapeutics (NLTX) Competitors

NLTX vs. ALVO, AKTS, EVO, CRON, and SVRA

How does Neoleukin Therapeutics compare to Alvotech?

Summary

How does Neoleukin Therapeutics compare to Aktis Oncology?

Summary

How does Neoleukin Therapeutics compare to Evotec?

Summary

How does Neoleukin Therapeutics compare to Cronos Group?

Summary

How does Neoleukin Therapeutics compare to Savara?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NLTX vs. The Competition

Neoleukin Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neoleukin Therapeutics (NLTX) Competitors

NLTX vs. ALVO, AKTS, EVO, CRON, and SVRA

How does Neoleukin Therapeutics compare to Alvotech?

Do analysts prefer NLTX or ALVO?

Which has more volatility and risk, NLTX or ALVO?

Is NLTX or ALVO more profitable?

Which has preferable earnings & valuation, NLTX or ALVO?

Does the media refer more to NLTX or ALVO?

Do institutionals and insiders have more ownership in NLTX or ALVO?

Summary

How does Neoleukin Therapeutics compare to Aktis Oncology?

Is AKTS or NLTX more profitable?

Do insiders and institutionals have more ownership in AKTS or NLTX?

Do analysts prefer AKTS or NLTX?

Does the media prefer AKTS or NLTX?

Which has better earnings and valuation, AKTS or NLTX?

Summary

How does Neoleukin Therapeutics compare to Evotec?

Do analysts rate EVO or NLTX?

Does the media favor EVO or NLTX?

Which has preferable earnings and valuation, EVO or NLTX?

Which has more risk and volatility, EVO or NLTX?

Is EVO or NLTX more profitable?

Do insiders & institutionals believe in EVO or NLTX?

Summary

How does Neoleukin Therapeutics compare to Cronos Group?

Which has more risk & volatility, CRON or NLTX?

Which has preferable valuation & earnings, CRON or NLTX?

Do institutionals & insiders have more ownership in CRON or NLTX?

Is CRON or NLTX more profitable?

Do analysts rate CRON or NLTX?

Does the media prefer CRON or NLTX?

Summary

How does Neoleukin Therapeutics compare to Savara?

Does the media refer more to NLTX or SVRA?

Do insiders & institutionals hold more shares of NLTX or SVRA?

Which has more volatility & risk, NLTX or SVRA?

Do analysts rate NLTX or SVRA?

Which has higher valuation and earnings, NLTX or SVRA?

Is NLTX or SVRA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NLTX vs. The Competition

Neoleukin Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools